Trustee: American Kidney Fund (no compensation) Grant/Research Support: Physician Services Inc* *monies paid to institution Tetsuo Shoji, MD, PhD, is affiliated with the Department of Geriatrics and Vascular Medicine, Osaka City Univer- sity Graduate School of Medicine, Osaka, Japan. He studied medicine in the medical school of Osaka City University and then worked at the Second Department of Internal Medicine, Osaka City University Hospital. He is interested in dyslipidemia, and other metabolic and endocrine alterations as factors affecting CVD in patients with CKD. He is a member of the Japanese Society for Dialysis Therapy (JSDT), the Japanese Society of Nephrology (JSN), the Japan Atherosclerosis Society (JAS), the Japan Diabetes Society (JDS) and others. He was the recipient of the Society Award from JSDT and a Work Group Member for the following guideline groups: 2011 JSDT Guidelines for the Evaluation and Treatment of Cardiovascular Complications in HD Patients; 2012 JSDT Guideline for CKD-Mineral Bone Disorder; 2012 JAS Guidelines for Prevention of Atherosclerotic CVD; and 2013 JSN Guideline for the Treatment of CKD. Grant/Research Support: Astellas;* Daiichi Sankyo;* Dainippon Sumitomo;* Mochida;* Shionogi* Speaker: Astellas; Daiichi Sankyo; Kowa; Kyowa Hakko Kirin; Merck Sharp & Dohme; Mochida; Pfizer; Shionogi *monies paid to institution biographic and disclosure information Robert J Walker, MBChB, MD (Otago), FRACP, FASN, FAHA, is Professor of Medicine and Head of the Department of Medicine at Dunedin School of Medicine, University of Otago, New Zealand. He is also a Consultant Nephrologist and Head of Nephrology at Healthcare Otago. Dr Walker has a broad base of translational renal research with interests in renal pharmacology, renal pathophysiology and drug nephrotoxicity, linked to the ongoing clinical research interests in the regulation of renal and cardiovascular hemodynamics and AKI. 